, Tracking Stock Market Picks
Enter Symbol:
Rating: AVII

Sarepta Therapeutics Inc (NASDAQ: SRPT) reiterated to Neutral by Piper Jaffray

Monday,  Jan 18, 2016  8:25 AM ET by Kristen Bailey

Piper Jaffray reiterated Sarepta Therapeutics Inc (NASDAQ: SRPT) to
Neutral. Piper Jaffray rated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Neutral on 01/15/2016, when the price was $13.76.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy